|
Market Closed -
NYSE
16:00:00 2025-07-24 EDT
|
5-day change | 1st Jan Change | ||
| 11.13 USD | +0.27% |
|
-.--% | - |
| 25-07-27 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Biotechnology Select Industry Index | CI |
| 25-07-27 | Verve Therapeutics, Inc.(NasdaqGS:VERV) dropped from S&P Global BMI Index | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Gene Research and Development | ||||||
Research And Development Of Gene Editing Medicines | - | - | 1.94M | 11.76M | 32.33M | |
Total Assets | 78.41M | 384M | 679M | 753M | 647M | |
Income Tax Expense | - | - | 53K | 275K | 349K | |
CAPEX | -3.42M | -4.36M | -13.23M | -9.28M | -3.74M | |
EBT | -45.7M | -120M | -157M | -200M | -198M | |
D&A | 1.33M | 1.54M | 2.8M | 5.46M | 6.75M | |
Operating Income | -40.63M | -87.07M | -166M | -223M | -229M | |
Net Income | -45.7M | -120M | -157M | -200M | -199M |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
United States | - | - | 1.94M | 11.76M | 32.33M | |
Total Assets | 78.41M | 384M | 679M | 753M | 647M | |
Income Tax Expense | - | - | 53K | 275K | 349K | |
D&A | 1.33M | 1.54M | 2.8M | 5.46M | 6.75M | |
CAPEX | -3.42M | -4.36M | -13.23M | -9.28M | -3.74M | |
Net Income | -45.7M | -120M | -157M | -200M | -199M | |
EBT | -45.7M | -120M | -157M | -200M | -198M | |
Operating Income | -40.63M | -87.07M | -166M | -223M | -229M |
- Stock Market
- Stocks
- VERV Stock
- Financials VERE THER
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
